Description
Ramosetronisaninhibitorof5-HT3receptorsthatiscurrentlyinclinicaltrialsasatreatmentforchemotherapeutic-inducedorpostoperativenauseaandvomiting;italsotreatsinflammatorybowelsyndrome(IBS).Ramosetronexhibitsantiemeticandanti-inflammatoryactivities.Ramosetroninhibits5-fluorouracil-inducedinflammationandmucositis,decreasingexpressionofIL-6,TNF-α,andIL-1β,decreasingactivationofcaspases3and8,andpreventingapoptosis;thisresultsindecreasedbodyweightlossanddiseaseseverity.Thiscompoundalsoallowsgastrointestinaltransitandinhibitsstress-inducedabnormaldefecationinvivo.
References
KimWJ,KangH,ShinHY,etal.Ramosetron,midazolam,andcombinationoframosetronandmidazolamforpreventionofpostoperativenauseaandvomiting:aProspective,randomized,double-blindstudy.JIntMedRes.2013Aug;41(4):1203-13.PMID:23766412.
ParkYM,LeeYJ,LeeYH,etal.EffectsoframosetronongastrointestinaltransitofGuineapig.JNeurogastroenterolMotil.2013Jan;19(1):36-41.Erratumin:JNeurogastroenterolMotil.2013;19(2):275.PMID:23350045.
YasudaM,KatoS,YamanakaN,etal.5-HT3receptorantagoNISTsameliorate5-fluorouracil-inducedintestinalmucositisbysuppressionofapoptosisinmurineintestinalcryptcells.BrJPharmacol.2013Mar;168(6):1388-400.PMID:23072534.
